Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Basal Cell | 5 | 2023 | 565 | 1.860 |
Why?
|
| Cosmetic Techniques | 5 | 2021 | 149 | 1.760 |
Why?
|
| Mohs Surgery | 6 | 2023 | 217 | 1.600 |
Why?
|
| Skin Neoplasms | 11 | 2023 | 5863 | 1.500 |
Why?
|
| Dermatology | 3 | 2022 | 905 | 0.730 |
Why?
|
| Keratinocytes | 3 | 2022 | 876 | 0.720 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2022 | 4058 | 0.720 |
Why?
|
| Warts | 1 | 2019 | 66 | 0.660 |
Why?
|
| Isotretinoin | 2 | 2017 | 134 | 0.650 |
Why?
|
| Nose Neoplasms | 1 | 2021 | 250 | 0.650 |
Why?
|
| Chemexfoliation | 1 | 2017 | 11 | 0.590 |
Why?
|
| Dermabrasion | 1 | 2017 | 17 | 0.590 |
Why?
|
| Cancer Care Facilities | 1 | 2020 | 427 | 0.580 |
Why?
|
| Dermatologic Agents | 2 | 2017 | 313 | 0.540 |
Why?
|
| Drug Storage | 1 | 2016 | 52 | 0.520 |
Why?
|
| Skin Transplantation | 1 | 2021 | 1096 | 0.510 |
Why?
|
| Syringes | 1 | 2016 | 58 | 0.510 |
Why?
|
| Skin | 5 | 2024 | 4503 | 0.490 |
Why?
|
| Drug Contamination | 1 | 2016 | 151 | 0.470 |
Why?
|
| Organizational Objectives | 1 | 2016 | 426 | 0.470 |
Why?
|
| Papillomavirus Vaccines | 1 | 2019 | 497 | 0.430 |
Why?
|
| Laser Therapy | 2 | 2017 | 1107 | 0.430 |
Why?
|
| Lidocaine | 1 | 2016 | 546 | 0.410 |
Why?
|
| Surgical Flaps | 1 | 2021 | 1682 | 0.410 |
Why?
|
| Epinephrine | 1 | 2016 | 794 | 0.400 |
Why?
|
| Patients | 1 | 2019 | 908 | 0.400 |
Why?
|
| Motivation | 2 | 2019 | 2020 | 0.390 |
Why?
|
| Melanoma | 2 | 2021 | 5706 | 0.390 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 2914 | 0.390 |
Why?
|
| Fellowships and Scholarships | 2 | 2021 | 1135 | 0.390 |
Why?
|
| Carcinoma | 1 | 2021 | 2332 | 0.340 |
Why?
|
| Health Behavior | 1 | 2021 | 2650 | 0.320 |
Why?
|
| Anesthetics, Local | 1 | 2016 | 1005 | 0.320 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 2931 | 0.280 |
Why?
|
| Neoplasm Staging | 4 | 2021 | 11244 | 0.250 |
Why?
|
| Education, Medical, Graduate | 2 | 2019 | 2420 | 0.240 |
Why?
|
| Skin Diseases | 3 | 2019 | 1085 | 0.240 |
Why?
|
| Internship and Residency | 4 | 2021 | 5953 | 0.240 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2024 | 491 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 6 | 2020 | 7454 | 0.210 |
Why?
|
| Cicatrix | 2 | 2017 | 798 | 0.190 |
Why?
|
| Protective Clothing | 1 | 2021 | 103 | 0.180 |
Why?
|
| Photopheresis | 1 | 2010 | 35 | 0.170 |
Why?
|
| Organizations, Nonprofit | 1 | 2020 | 105 | 0.170 |
Why?
|
| Hutchinson's Melanotic Freckle | 1 | 2020 | 26 | 0.170 |
Why?
|
| Sunscreening Agents | 1 | 2021 | 139 | 0.170 |
Why?
|
| Tarlov Cysts | 1 | 2009 | 13 | 0.170 |
Why?
|
| Adenocarcinoma, Sebaceous | 1 | 2019 | 21 | 0.170 |
Why?
|
| Neuromuscular Agents | 1 | 2021 | 148 | 0.170 |
Why?
|
| Botulinum Toxins | 1 | 2021 | 191 | 0.170 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2019 | 40 | 0.170 |
Why?
|
| Genes, p16 | 1 | 2008 | 159 | 0.150 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2021 | 238 | 0.150 |
Why?
|
| Cellulitis | 1 | 2018 | 206 | 0.130 |
Why?
|
| Humans | 30 | 2024 | 768166 | 0.130 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 863 | 0.120 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2020 | 737 | 0.120 |
Why?
|
| Microscopy, Fluorescence | 1 | 2022 | 2633 | 0.120 |
Why?
|
| Thoracic Vertebrae | 1 | 2009 | 613 | 0.120 |
Why?
|
| Physician's Role | 1 | 2021 | 925 | 0.110 |
Why?
|
| Self Efficacy | 1 | 2018 | 643 | 0.110 |
Why?
|
| Patient Education as Topic | 2 | 2021 | 2337 | 0.110 |
Why?
|
| Body Image | 1 | 2019 | 646 | 0.110 |
Why?
|
| Papillomaviridae | 1 | 2019 | 1140 | 0.110 |
Why?
|
| Accreditation | 1 | 2016 | 476 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 3620 | 0.110 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 1793 | 0.100 |
Why?
|
| Interpersonal Relations | 1 | 2019 | 1434 | 0.090 |
Why?
|
| Interviews as Topic | 1 | 2019 | 2741 | 0.090 |
Why?
|
| Guideline Adherence | 1 | 2020 | 2235 | 0.090 |
Why?
|
| Lower Extremity | 1 | 2018 | 1216 | 0.090 |
Why?
|
| Reoperation | 1 | 2020 | 4329 | 0.080 |
Why?
|
| Dendritic Cells | 1 | 2010 | 2747 | 0.080 |
Why?
|
| Retrospective Studies | 5 | 2021 | 81762 | 0.080 |
Why?
|
| United States | 4 | 2021 | 73039 | 0.080 |
Why?
|
| Aged | 5 | 2021 | 171504 | 0.080 |
Why?
|
| Male | 10 | 2024 | 364719 | 0.080 |
Why?
|
| Disease Management | 1 | 2019 | 2536 | 0.070 |
Why?
|
| Middle Aged | 7 | 2024 | 223492 | 0.070 |
Why?
|
| Gene Expression | 1 | 2010 | 7598 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 3706 | 0.070 |
Why?
|
| Qualitative Research | 1 | 2019 | 3140 | 0.070 |
Why?
|
| Veterans | 1 | 2021 | 2669 | 0.070 |
Why?
|
| Collagen Type XI | 1 | 2006 | 21 | 0.070 |
Why?
|
| Biopsy | 1 | 2019 | 6793 | 0.070 |
Why?
|
| Collagen Type IX | 1 | 2006 | 20 | 0.070 |
Why?
|
| Receptors, Mitogen | 1 | 2006 | 61 | 0.070 |
Why?
|
| Quality of Life | 2 | 2019 | 13490 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 8542 | 0.070 |
Why?
|
| Emotions | 1 | 2019 | 2767 | 0.070 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2006 | 101 | 0.070 |
Why?
|
| Risk | 1 | 2018 | 9613 | 0.070 |
Why?
|
| Wound Healing | 1 | 2017 | 2809 | 0.070 |
Why?
|
| Clinical Competence | 2 | 2019 | 4858 | 0.060 |
Why?
|
| Curriculum | 1 | 2019 | 3782 | 0.060 |
Why?
|
| Female | 10 | 2024 | 397192 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 59629 | 0.060 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 7852 | 0.060 |
Why?
|
| Societies, Medical | 1 | 2016 | 3968 | 0.060 |
Why?
|
| Patient Selection | 1 | 2016 | 4260 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 9419 | 0.060 |
Why?
|
| Temporomandibular Joint Disorders | 1 | 2006 | 227 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 5367 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2010 | 11669 | 0.050 |
Why?
|
| Risk Factors | 2 | 2021 | 74944 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2019 | 65371 | 0.050 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2024 | 232 | 0.050 |
Why?
|
| Drug Eruptions | 1 | 2024 | 335 | 0.050 |
Why?
|
| Pamphlets | 1 | 2021 | 71 | 0.050 |
Why?
|
| Incidence | 1 | 2019 | 21538 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2008 | 11928 | 0.040 |
Why?
|
| Adult | 5 | 2024 | 223646 | 0.040 |
Why?
|
| Cartilage, Articular | 1 | 2006 | 1104 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2006 | 1627 | 0.040 |
Why?
|
| Beauty | 1 | 2018 | 41 | 0.040 |
Why?
|
| Osteoarthritis | 1 | 2006 | 1072 | 0.040 |
Why?
|
| Ohio | 1 | 2019 | 321 | 0.040 |
Why?
|
| Injections | 1 | 2021 | 840 | 0.040 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2010 | 210 | 0.040 |
Why?
|
| Organizational Innovation | 1 | 2021 | 540 | 0.040 |
Why?
|
| Florida | 1 | 2019 | 417 | 0.040 |
Why?
|
| Neurotransmitter Agents | 1 | 2021 | 663 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2024 | 1801 | 0.040 |
Why?
|
| Happiness | 1 | 2018 | 170 | 0.030 |
Why?
|
| Skin Aging | 1 | 2018 | 140 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 18065 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2010 | 1903 | 0.030 |
Why?
|
| Young Adult | 2 | 2019 | 60066 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2008 | 858 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2010 | 1864 | 0.030 |
Why?
|
| Face | 1 | 2021 | 1029 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2010 | 1251 | 0.030 |
Why?
|
| Cell Separation | 1 | 2010 | 1728 | 0.030 |
Why?
|
| Video Recording | 1 | 2019 | 976 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2019 | 2862 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 4580 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 3800 | 0.020 |
Why?
|
| Reward | 1 | 2018 | 981 | 0.020 |
Why?
|
| Monocytes | 1 | 2010 | 2605 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 4648 | 0.020 |
Why?
|
| Hospitals | 1 | 2023 | 3886 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 5902 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2021 | 2523 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 6082 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2008 | 4176 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2021 | 3269 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2010 | 3049 | 0.020 |
Why?
|
| Aging | 1 | 2006 | 8744 | 0.020 |
Why?
|
| Self Report | 1 | 2018 | 3773 | 0.020 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2006 | 139 | 0.020 |
Why?
|
| Collagen Type II | 1 | 2006 | 151 | 0.020 |
Why?
|
| Protein Binding | 1 | 2008 | 9343 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2018 | 9669 | 0.020 |
Why?
|
| Osteochondrodysplasias | 1 | 2006 | 183 | 0.020 |
Why?
|
| Decision Making | 1 | 2018 | 3953 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2019 | 54926 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2006 | 1754 | 0.010 |
Why?
|
| Pneumonia, Viral | 1 | 2021 | 3238 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2008 | 12800 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 14729 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2008 | 19015 | 0.010 |
Why?
|
| Pandemics | 1 | 2021 | 8748 | 0.010 |
Why?
|
| Mice | 2 | 2024 | 82029 | 0.010 |
Why?
|
| Adolescent | 2 | 2018 | 89169 | 0.010 |
Why?
|
| Heterozygote | 1 | 2006 | 2798 | 0.010 |
Why?
|
| Prognosis | 1 | 2019 | 30010 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 20760 | 0.010 |
Why?
|
| Animals | 2 | 2024 | 169246 | 0.010 |
Why?
|
| Time Factors | 1 | 2017 | 40218 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 11095 | 0.010 |
Why?
|
| Genotype | 1 | 2006 | 13045 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 18349 | 0.000 |
Why?
|
| Mutation | 1 | 2006 | 30238 | 0.000 |
Why?
|
Concepts
(173)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(20)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_